Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Merck Abandons $32 Billion Revolution Medicines Acquisition Over Price Dispute

Fineline Cube Jan 26, 2026
Company Deals

Dizal Pharmaceutical Files for Hong Kong IPO, Backed by AstraZeneca and First‑in‑Class Oncology Assets

Fineline Cube Jan 26, 2026
Company Deals

HealZen Inks Global DAC Partnership, Second TPD Deal Following J&J Alliance

Fineline Cube Jan 26, 2026
Company Deals

Novo Nordisk Expands Aspect Biosystems Partnership for Diabetes Cell Therapy

Fineline Cube Jan 23, 2026
Company Deals

Sisram Medical Partners with Fosun Pharma Subsidiary on Local Production Base

Fineline Cube Jan 23, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Drug

Zhongsheng’s RAY1225 Wins NMPA Approval for Obesity‑Sleep Apnea Study as Phase III Wraps Up

Fineline Cube Jan 26, 2026
Company Drug

Changchun High‑Tech’s GenSci145 PI3Kα Inhibitor Cleared by NMPA for Solid Tumor Study

Fineline Cube Jan 26, 2026
Company

GSK Leaves BIO, Joining Other Major Companies in Withdrawing Membership

Fineline Cube Nov 11, 2024

GlaxoSmithKline (GSK; NYSE: GSK), a leading pharmaceutical company based in the UK, has reportedly withdrawn...

Company Deals

ATLATL and Takeda Enter MoU to Collaborate on Early-Stage Drug Development and Innovation

Fineline Cube Nov 11, 2024

ATLATL, an innovation incubator and global life science research and development (R&D) platform, has signed...

Company Deals Drug

Alteogen Secures Exclusive Licensing Deal with Daiichi Sankyo for Subcutaneous Enhertu

Fineline Cube Nov 11, 2024

Alteogen Inc. (KOSDAQ: 196170), a South Korea-based biotechnology company, has announced an exclusive licensing agreement...

Company Deals

Baheal Pharmaceutical Group Leads USD 78 Million Investment in ZAP Surgical Systems

Fineline Cube Nov 11, 2024

Baheal Pharmaceutical Group (SHE: 301015), a leading health services and distribution company based in China,...

Company Deals

Pfizer Partners with Beijing Mabworks and KYinno Biotechnology on Multiple Myeloma Treatments in China

Fineline Cube Nov 11, 2024

At the 7th China International Import Expo (CIIE), Chinese firms Beijing Mabworks Biotech Co., Ltd,...

Company Drug

AstraZeneca’s Tezspire Meets Phase III Co-Primary Endpoints in CRSwNP Study

Fineline Cube Nov 11, 2024

AstraZeneca Inc., (AZ, NASDAQ: AZN), a leading UK pharmaceutical company, has announced positive high-level results...

Company Medical Device

Sino Medical Sciences Technology Secures Marketing Approval in Peru for HT Supreme Stent System

Fineline Cube Nov 11, 2024

Sino Medical Sciences Technology Inc., (SHA: 688108), a leading Chinese medical technology company, has announced...

Company Drug

Jiangsu Kanion Pharmaceutical Gets FDA Approval to Test KYS202004A for Psoriasis

Fineline Cube Nov 11, 2024

Jiangsu Kanion Pharmaceutical Co., Ltd (SHA: 600557), a Chinese pharmaceutical company, has announced that it...

Company Drug

J&J Submits Regulatory Filings for Darzalex Faspro and Subcutaneous Daratumumab

Fineline Cube Nov 11, 2024

Johnson & Johnson (J&J, NYSE: JNJ) has announced the submission of regulatory filings for its...

Company Drug

Jiangsu Hengrui Pharmaceuticals Receives NMPA Clearance for Multiple Clinical Trials of Oncology Drugs

Fineline Cube Nov 11, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a Chinese pharmaceutical company, has announced that it...

Company Drug

Alphamab Oncology Presents JSKN033 Phase I/II Study Results at SITC 2024

Fineline Cube Nov 11, 2024

Alphamab Oncology (HKG: 9966), a China-based biopharmaceutical company, has announced the presentation of the latest...

Company Drug

Sino Biopharmaceutical Ltd Receives NMPA Approval for KRAS G12C Inhibitor Garsorasib

Fineline Cube Nov 11, 2024

Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company in China, has announced that it...

Company Deals Drug

Daiichi Sankyo and Alteogen Sign $300 Million Deal to Develop Subcutaneous Enhertu

Fineline Cube Nov 9, 2024

Daiichi Sankyo (TYO: 4568), a leading Japanese pharmaceutical company, has entered into a potentially $300...

Company Drug

Dizal Pharmaceutical Submits NDA to FDA for Sunvozertinib as NSCLC Therapy

Fineline Cube Nov 9, 2024

Dizal Pharmaceutical Co., Ltd (SHA: 688192), a Chinese pharmaceutical company, has announced the submission of...

Company Deals

MGI Tech Co., Ltd Partners with Human Cell Atlas Consortium to Advance Cell Mapping

Fineline Cube Nov 8, 2024

China-based gene sequencing specialist, MGI Tech Co., Ltd, (SHA: 688114) has announced a commercial collaboration...

Company

AstraZeneca Confirms Executive Vice President Leon Wang’s Detention in China

Fineline Cube Nov 8, 2024

AstraZeneca Inc., (AZ, NASDAQ: AZN), a leading UK pharmaceutical company, has provided an update to...

Company Deals

Jiangsu Kanion Pharmaceutical to Acquire Xintrum Pharmaceuticals for RMB 270 Million

Fineline Cube Nov 8, 2024

Jiangsu Kanion Pharmaceutical Co., Ltd (SHA: 600557), a China-based pharmaceutical company, has announced its intention...

Company Drug

Ascletis Pharma’s ASC47 Showcases Promising Weight Loss Results in Phase I Clinical Trial

Fineline Cube Nov 8, 2024

Ascletis Pharma Inc. (HKG: 1672), a China-based pharmaceutical company, has announced positive results from a...

Company Deals

Nuwacell Biotechnologies Secures RMB150 Million in Series B Financing for iPSC Therapies

Fineline Cube Nov 8, 2024

Nuwacell Biotechnologies Co., Ltd., a specialist in induced pluripotent stem cell (iPSC) technology based in...

Company Deals

Shanghai Henlius Biotech Partners with SVAX to Boost MENAT Region’s Access to Biological Drugs

Fineline Cube Nov 8, 2024

Shanghai Henlius Biotech Inc. (HKG: 2696), a leading Chinese biotech company, has entered into a...

Posts pagination

1 … 217 218 219 … 613

Recent updates

  • Merck Abandons $32 Billion Revolution Medicines Acquisition Over Price Dispute
  • Dizal Pharmaceutical Files for Hong Kong IPO, Backed by AstraZeneca and First‑in‑Class Oncology Assets
  • Zhongsheng’s RAY1225 Wins NMPA Approval for Obesity‑Sleep Apnea Study as Phase III Wraps Up
  • Changchun High‑Tech’s GenSci145 PI3Kα Inhibitor Cleared by NMPA for Solid Tumor Study
  • Eisai/Biogen’s LEQEMBI Autoinjector Wins FDA Priority Review for Weekly Alzheimer’s Dosing
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Merck Abandons $32 Billion Revolution Medicines Acquisition Over Price Dispute

Company Deals

Dizal Pharmaceutical Files for Hong Kong IPO, Backed by AstraZeneca and First‑in‑Class Oncology Assets

Company Drug

Zhongsheng’s RAY1225 Wins NMPA Approval for Obesity‑Sleep Apnea Study as Phase III Wraps Up

Company Drug

Changchun High‑Tech’s GenSci145 PI3Kα Inhibitor Cleared by NMPA for Solid Tumor Study

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.